Vector Science and Caresyntax Partner to Build Surgical Evidence Data

The program focuses on measuring postoperative recovery by tracking opioid utilization, hospital length of stay, and patient-reported pain scores. Caresyntax will oversee the design and operation of this infrastructure, starting with baseline data collection to establish current standards of care. These metrics will serve as a comparison point for procedures utilizing VectorMist, which delivers atomized medication directly to surgical sites. By creating a prospective comparative registry, the partnership allows hospitals to benchmark their institutional performance against peers, providing the objective outcomes data now demanded by purchasing committees.

Beyond the immediate rollout, both companies are evaluating the expansion of this evidence architecture to Vector’s wider portfolio, including its peptide therapeutics. Dr. Brad Worthington, Chief Medical Officer at Vector, noted that the partnership integrates a feedback loop into the technology from the outset to build surgeon confidence. Dr. Bruce Ramshaw, Chief Medical Informatics Officer of Caresyntax, described the effort as a necessary shift in medtech, where companies must develop clinical evidence engines in parallel with their hardware to provide measurable insight into every procedure.